Honing Biosciences


How are novel therapies working?


CAR-T cells therapyCAR-T cells (Chimeric Antigen Receptor T cells) have now been proven to have an extraordinary capacity to kill cancer cells and have led to complete remissions in previously incurable patients.
However this approach has also led to deaths and clinical holds of current clinical trials. These side effects are due at least in part to the continued expression of these CAR-T molecules.
One possible solution for preventing these deaths would be to engineer an activable switch in the CAR. This switch would allow turning-off the surface expression of the CAR therefore preventing the possible side effects including death, which may occur when the expression of the CAR is permanent.
Checkpoint inhibitorsMechanisms by which tumor cells escape the surveillance of our immune system have been discovered recently. The ``tumor killer" T cells express surface molecules such as PD1. To overcome and prevent their own killing tumor, cells manage to induce surface expression of a corresponding molecule called PDL1. Then at the time of the tumor-T cell interaction, PDL1 binds PD1 with this binding turning off the killing machinery of T cells. The immune system is effectively ``checked" by the tumor cells. A number of such molecular interactions have been identified and the molecules involved have been given the general name ``checkpoints".















CellTune™


Q

CARTune(TM): CellTune(TM) for CART

The scientific teams of Honing Biosciences led by Franck Perez and Sebastian Amigorena are world-renowned leaders in the field of intracellular molecular trafficking and immunity and they have designed successfully (and patented) various forms of clever switches, which can be applied to CAR-T cells. The first R&D axis of Honing Biosciences will be to render CARs switchable.
T
CellTune(TM) and Checkpoint inhibitors
Honing Biosciences has developed a very novel technology allowing to select small antibodies ("nanobodies") based on proprietary scaffold, which they can deliver intracellularly. These nanobodies can inhibit the cell surface expression of any surface expressed molecules such as checkpoints by maintaining them in intracellular compartments.